This collaboration focuses on enabling complex decision-making by combining results from point-of-care tests with smartphone data creating essential opportunities in countries with limited access to sophisticated laboratory testing.
This work will explore the feasibility of integrating wireless technologies intended to simplify field-based workflows and to reduce dependence on wired power sources into OmniVeritaM the smartphone-enabled portable diagnostic platform being developed by Biological Dynamics.
The ultimate objective of the portable is to enable affordable, user-friendly, and sensitive diagnostic testing for high-burden conditions that can be successfully deployed to resource-poor settings on a global scale.
The technology is powered by Biological Dynamics' novel isolation platform, Verita, which enables the isolation of circulating biomarkers such as cell-free DNA and exosomes from whole blood, serum, and plasma without the need to pre-process samples.
The company is currently applying the cutting-edge isolation capabilities of Verita to develop the next generation of lab and point-of-care tests for the early detection and treatment response monitoring of cancer.
Biological Dynamics is a diagnostic company committed to improving global health outcomes by empowering healthcare communities with accessible diagnostics.
Biological Dynamics' proprietary technology platform, Verita, isolates nanoparticles and macromolecules directly from whole blood, serum, or plasma without the need for pre-processing samples.
The company is developing a portfolio of novel oncology and infectious disease products designed to enable early detection and individualised treatment response monitoring. In addition to lab-focused products, Biological Dynamics is also developing a smartphone-enabled portable version of the platform with the goal of bringing blood-based DNA testing into the home.
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer
Oxford Biomedica to acquire ABL Europe
RedHill Biopharma granted five years' market exclusivity for Talicia by US FDA
SK bioscience signs development licensing agreement with Hilleman Laboratories
Poolbeg Pharma expands patent portfolio with Immunomodulator II approval in Japan
NeoImmuneTech's NT-I7 receives US FDA Orphan Drug Designation